Biodexa announces milestone in Serenta Phase 3 FAP trial
Biodexa announces a major milestone for its Serenta registrational Phase 3 trial in FAP, with no further details or catalyst supplied in the alert.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.